{"ticker": {"uuid": "ee9e823a-29ad-4b12-ac14-4b74a43800c5", "symbol": "KZIA", "name": "Kazia Therapeutics Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director", "summary": "Kazia Therapeutics (KZIA) has granted 100,000 employee stock options over ADSs to David Cain, its Director, CMC. The options have an exercise price of $9.10 per ADS and will vest in tranches, starting January 8, 2027, and expiring on January 8, 2029. This equity grant aims to pro", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-b9c21773c4e0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T05:12:52", "published_display": "09 Jul 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOUDBaRUhFYjYwLXRPblpaMTJqMUhkdlNtbDJlcGxhbmpNSU1WR1RJMTVabUpKQUtXQ29VZHpqZ3FKNTEzYmJFU20tQ2V1aV80dTdBWVlrOW45enlnMDB6U20wM0ZQNTN0cEZiMS1la1IyWm5ibmNZTGpnZ1p6VUhYUUI4X2M5X1c3NFJlbllXVC1EZ0hXa2ZvdmVLR0p5VnpXN3hCbTR0bE9KWDgwOWpWVXhMaFpWWHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T20:58:42+00:00", "published_display": "08 Jul 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78", "summary": "Kazia Therapeutics director Robert F. Apple was granted 75,000 stock options over ADSs on January 8, 2026, with an exercise price of $6.78 per ADS. These options, awarded for no cash consideration, will vest on January 8, 2027, and have an expiration date of January 8, 2029. This", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-b3f618467f3b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) grants director 100,000 stock options", "summary": "Kazia Therapeutics director Steven R. S. Coffey was granted 100,000 employee stock options over ADSs with an exercise price of $9.10 per ADS. The options were granted for no consideration, vest on January 8, 2027, and expire on January 8, 2029. This transaction was approved by th", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-782de1b8b8d2.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance", "summary": "Kazia Therapeutics reported that Jeffrey Bonacorda, VP, Finance and Controller, received a grant of 150,000 employee stock options (ADSs). These options have an exercise price of $6.78 per ADS, based on the Nasdaq closing price on January 8, 2026, and will vest over three years s", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-070fdddeb4c1.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant", "summary": "KAZIA THERAPEUTICS LTD CEO John E. Friend II was granted 150,000 restricted share units (RSUs) and 500,000 employee stock options. These equity compensation awards, approved by the Remuneration Committee, involve an exercise price of $6.78 per ADS for the options and a vesting sc", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-3f441aa5b6e4.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Initiates Kazia Therapeutics at Buy With $34 Price Target", "summary": "BTIG has initiated coverage of Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $34. This rating indicates a strong positive outlook for the company's stock by the investment firm.", "url": "https://www.moomoo.com/news/post/72328358/btig-initiates-kazia-therapeutics-at-buy-with-34-price-target", "source_name": "Moomoo", "published_at": "2026-07-02T03:09:21", "published_display": "02 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $34", "summary": "BTIG has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating. The firm has set a price target of $34 for the pharmaceutical company. This new rating suggests a positive outlook from BTIG on Kazia Therapeutics' stock performance.", "url": "https://www.moomoo.com/news/post/72330496/btig-initiates-kazia-therapeutics-kziaus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-01T14:40:36", "published_display": "01 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG initiates Kazia Therapeutics stock with buy on cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWkhodWtMWEpzNnRlNE9Odm1meWt5ZnRLcUtBQlJWM01UTkpDMGV6Q2REeUxHczM3T0Y5UV9BVmp5YjRrWDVPT3p0Mnk2N0kxRUc4R3Q3eWlqbkNHakNjNTlkU0szb1hDeXNNaG81dUN0ZmhYc2JRd0ozYnNZNTgzanoxS3g3MjVuSmlvM0VYUElEdnZ3S2MycnF4Q0RHRE0yU3gwM29rbE93R09JY0V5ZHNjRVV3QkdWaEpBNWozdFY?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T11:08:00+00:00", "published_display": "01 Jul 2026 11:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com", "summary": "BTIG has initiated coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and a price target of $34.00, citing the company's advanced oncology pipeline, particularly its drug paxalisib. While the stock has seen a significant return in the past year, InvestingPro suggests ", "url": "https://ca.investing.com/news/stock-market-news/btig-initiates-kazia-therapeutics-stock-with-buy-on-cancer-drug-93CH-4715757", "source_name": "Investing.com Canada", "published_at": "2026-07-01T11:16:27", "published_display": "01 Jul 2026 11:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA)", "summary": "Kazia Therapeutics Ltd (NASDAQ:KZIA) financial data, including actual results and analyst estimates, is available on TradingView. The platform allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. Us", "url": "https://www.tradingview.com/symbols/NASDAQ-KZIA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:10:28", "published_display": "26 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KZIA SEC Filings - Kazia Therapeuti 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Kazia Therapeutics (KZIA) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It features AI-generated summaries, impact scoring, and sentiment analysis for each filing. Recent fil", "url": "https://www.stocktitan.net/sec-filings/KZIA/page-9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T00:10:28", "published_display": "24 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) grants CFO 200,000 options vesting to 2029", "summary": "Kazia Therapeutics reported that its CFO, James E. Levine, was granted 200,000 employee stock options over ADSs with an exercise price of $13.86 each. The options have a vesting schedule, with one-third vesting on June 1, 2026, and the remainder vesting annually thereafter, expir", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-745f53de3a7e.html", "source_name": "Stock Titan", "published_at": "2026-06-23T23:11:25", "published_display": "23 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPOEFheHlRV1ExczUyM1V5N3I1bU5fbU9sNXQxZ1NIaWR3em9pYXRNb0VTZlkzSkdBM0dZR09odmNoR0tJLW5ESlVpdlZyb1VzSE4wNlpWUk0xTVZ4eXRhWGdqSjBYYnE1Y3BXT0xoWXlEYUJxTG9UUUlIXy02OUR2WUVNak5oTEQ3cGZETVF4MV9YaFNZTEs4U0VXbklLanV1TnZnWDlnUVh1QVZDS29TOEwyMjRXbTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks", "summary": "This article lists Exchange Traded Funds (ETFs) that invest in Kazia Therapeutics Ltd Sponsored ADR stocks, presenting them as a way to invest in the company with lower risk. It provides a table detailing fund information such as market value, weight, issuer, management style, ex", "url": "https://www.tradingview.com/symbols/NASDAQ-KZIA/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-06-22T04:10:28", "published_display": "22 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kazia Therapeutics Ltd (KZIA), categorizing its performance by business segments and regional contributions. As of the report updated on March 4, 2025, relevant financial data for FY2021 and FY2022 concerning these breakdowns have not", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T05:10:25", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kazia Therapeutics Ltd (KZIA), detailing its current stock price, market cap, and various technical indicators. It outlines signals from MACD, RSI, KDJ, and Moving Averages, suggesting a \"Buy\" signal based on current technical analysi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:24", "published_display": "18 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "The article provides a detailed breakdown of Kazia Therapeutics Ltd's (KZIA) shareholder structure, listing major individual and institutional holders. It highlights that Jorey Chernett is the largest individual shareholder with 14.80%, while Alyeska Investment Group, L.P. is a s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T16:40:45", "published_display": "18 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Kazia Therapeutics Ltd (KZIA), indicating a current score of 0.00 with no change from the previous score. It lists key institutional shareholders and their holdings, such as Chernett (Jorey) with a significan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:12", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Kazia Therapeutics Ltd (KZIA), detailing various volatility, financial, and investment risk metrics. It includes data points such as Beta vs S&P 500 index, VaR, maximum drawdown, realized volatility, and Sharpe Ratio across different ti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:12", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Kazia Therapeutics Ltd (KZIA), including future EPS and revenue growth estimates. Based on an analysis of 4 analysts, the consensus target price for KZIA is USD 26.25, suggesting a 90.63% upside. The report highlights a \"Buy\" trend f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:12", "published_display": "18 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Kazia Therapeutics Ltd (KZIA), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The article also provides the stock's current pri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:12", "published_display": "18 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) CFO James E. Levine files initial Form 3", "summary": "Kazia Therapeutics' new Chief Financial Officer, James E. Levine, has filed an initial Form 3 with the SEC, indicating his beneficial ownership status. The filing clarifies his position as a reporting officer but shows no reported purchases, sales, or other transactions of KZIA s", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-3-kazia-therapeutics-ltd-initial-statement-of-beneficial-ownersh-d71ed8601687.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:40:21", "published_display": "15 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum Accelerates - Hot Stock Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPZW9XTjZCaklXSzNBXzJnTHJPbVhUYl8xa2NzV2tnUFhzTkhzV3dfSGYwakk0d1NnajZDYTgyalM4bWMxVTFYaHZGWHZRdld1cVdoRFNKa3E1QjJHUGpSR00xUE91bFYzWnJvUjZ0UUNheEJDSUd5UVhfU3p2RUxoZWVLSmk1MkJybEozS2ZOczktd2tKZVNjZHV2X0VTOFY4MWh6a1h6WFh1RC1jUi1EQnhJc3FTRFk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $32", "summary": "Lake Street has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating. The firm has set a price target of $32 for the company's stock, indicating a bullish outlook.", "url": "https://www.moomoo.com/news/post/71396594/lake-street-initiates-kazia-therapeutics-kziaus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-11T18:09:49", "published_display": "11 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Maintains Target Price $18", "summary": "H.C. Wainwright has reiterated its Buy rating for Kazia Therapeutics (KZIA.US), maintaining a price target of $18. This continued endorsement suggests the firm's confidence in the company's future performance and valuation. The decision to uphold both the rating and the price tar", "url": "https://www.moomoo.com/news/post/71064897/hc-wainwright-maintains-kazia-therapeutics-kziaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-07T01:09:17", "published_display": "07 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Raises Target Price to $30", "summary": "Maxim Group has reiterated its Buy rating on Kazia Therapeutics (KZIA.US) and increased its price target to $30. This update reflects the firm's continued positive outlook on the company's prospects.", "url": "https://www.moomoo.com/news/post/71079791/maxim-group-maintains-kazia-therapeutics-kziaus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-06-05T13:39:23", "published_display": "05 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) director details existing ADS option grants", "summary": "Kazia Therapeutics director Ebru Davidson has filed an initial ownership report (Form 3) detailing her existing option grants for the company's American Depositary Shares (ADSs). The filing reveals two ADS option positions, one for 75,000 ADSs with an exercise price of $8.00 and ", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-3-kazia-therapeutics-ltd-initial-statement-of-beneficial-ownersh-4ceedd43c69b.html", "source_name": "Stock Titan", "published_at": "2026-06-04T00:39:59", "published_display": "04 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxNbHNFdG5QNmJuM0FDLTdMUG96cnpGQUIxQ0hEV0wxZnI2ZGc5ZXdjdVg1M1hHakNHRTAwdzhBUEtsaVZNRVEwWXZYV0g0RmtQWmtadVZDMG1MazAyamhTVXpqQWtaaUZQUmZpSzRBdXZCdVZ5MldZUFJyNjF1QVMwYzl5N2MzX0g0WDhaV25IVjJwSkVJa3lrY1V6YmVnSlpvZkpkVUswRGRuMEt5ZHF3SjJEQmhycEhneURIa25VaVgwU3hIOE1lV0NrQTcwOFhncC1kX2xTcG5CZzlYM3lVWTdhcndLWnhCNDNpNzVMeV9BQ0FyV3RoejVkcjVSYTRoR2tMV2ZsNkFhb3RQaWZuRjJ3?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kazia Therapeutics Appoints James Levine as Chief Financial Officer", "summary": "Kazia Therapeutics has announced the appointment of James Levine as its new Chief Financial Officer, effective immediately. Mr. Levine brings extensive experience in biotech finance and will be crucial in managing the company's financial operations and strategic growth as it adva", "url": "https://www.moomoo.com/news/post/70928726/press-release-kazia-therapeutics-appoints-james-levine-as-chief-financial", "source_name": "Moomoo", "published_at": "2026-06-03T02:39:59", "published_display": "03 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Appoints James Levine as Chief Financial Officer", "summary": "Kazia Therapeutics has appointed James Levine as its Chief Financial Officer, effective June 1, 2026. Mr. Levine brings over two decades of experience in investment banking and financial leadership at publicly traded biotech companies, including roles at Cardiff Oncology and Cida", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kazia-therapeutics-appoints-james-levine-113000494.html", "source_name": "Market source", "published_at": "2026-06-02T23:11:25", "published_display": "02 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO", "summary": "Kazia Therapeutics has filed a prospectus supplement to register 10,700,211 American Depositary Shares (ADSs), representing 5,350,105,500 ordinary shares. Concurrently, the company announced the appointment of James Levine as its Chief Financial Officer, effective June 1, 2026, w", "url": "https://www.stocktitan.net/sec-filings/KZIA/424b3-kazia-therapeutics-ltd-prospectus-filed-pursuant-to-rule-424-b--84a4c2a60f27.html", "source_name": "Stock Titan", "published_at": "2026-06-02T15:08:57", "published_display": "02 Jun 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026", "summary": "Kazia Therapeutics Limited has announced the appointment of James Levine as its Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and financial leadership at publicly traded biotech companies, including roles at Ca", "url": "https://www.marketscreener.com/news/kazia-therapeutics-limited-announces-appointment-of-james-levine-to-chief-financial-officer-effecti-ce7f5ddedb81ff2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-02T14:39:13", "published_display": "02 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO", "summary": "Kazia Therapeutics Limited announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Mr. Levine's compensation package includes an annual base salary of US$475,000, a target bonus of 40% of base salary, and options for 200,000 American ", "url": "https://www.stocktitan.net/sec-filings/KZIA/6-k-kazia-therapeutics-ltd-current-report-foreign-issuer-fecd25e028c4.html", "source_name": "Stock Titan", "published_at": "2026-06-02T13:09:03", "published_display": "02 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kazia-therapeutics-expands-ongoing-phase-113000332.html", "source_name": "PR Newswire", "published_at": "2026-05-26T11:30:00+00:00", "published_display": "26 May 2026 11:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst (NASDAQ:KZIA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPVTNPSTIyLVI4TFQtZXRtejBUZ1BURzV0SjdwelF6anhvMXNpRjNvZ3A0UlJQLWtkZkxaUTNDQWRxWDNvekYxWmdfeEYwY0JNTGtyX25qRG01NGJqR2Q2aUlnSjZyQ01rbWRIMU9zRkVtT0laN2c4TkhJUk5HZWwyUVFlSWlMLWIwdmpQNnBWX1pCSFAtOHVfRnNDTWV3bDhNNEs0eE1yOE1sUlpOVDI1YU9B?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQTEZRc0RVRmFveTZXMG1SYS1TNkZtaDMzMWFtQjc4aTJHamNBVlRaX3BFazEzMnFCWXp0bEZVV0ozNGhfWndqWVRzTkVVME5lVnpNNHl1akFOZzZYUlQwRFREQVFDM2dPMzAyS1ZqN1cwU1NKZnI2cVJfR2NZNlZQTUotbFl6X0ZiWi1pZDRLTnBTbldVQndmMklxSjl5dkdvSmZNOGE4R0R1QlVJdDZz?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kazia adds AI-built cancer drug platform with lead candidate MSETC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTm9HM0Z5ZElxTnRhbkNFZVhjSmRsU0R4ZTdwT0hjQWxhV3VNSXlTSDc1ODc1dVVHQjhON1BBZ2pJUS1KdjRyRHh2cFdueDB4MUhGajNRZ2ZaS1BmbEh4Zi1yWnh3OHZ3T1V0UXAzWlhwTFNQRHVfVmtHWHpoWjBzenRoUUdzeWZ1S2ZHcjFvRVRsb01rd0g1alg1cWhHeDcxdHozbkcxNktsMDg0WUM5bVNxaTBncXFTNjVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director", "summary": "Kazia Therapeutics (KZIA) has granted 100,000 employee stock options over ADSs to David Cain, its Director, CMC. The options have an exercise price of $9.10 per ADS and will vest in tranches, starting January 8, 2027, and expiring on January 8, 2029. This equity grant aims to pro", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-b9c21773c4e0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T05:12:52", "published_display": "09 Jul 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOUDBaRUhFYjYwLXRPblpaMTJqMUhkdlNtbDJlcGxhbmpNSU1WR1RJMTVabUpKQUtXQ29VZHpqZ3FKNTEzYmJFU20tQ2V1aV80dTdBWVlrOW45enlnMDB6U20wM0ZQNTN0cEZiMS1la1IyWm5ibmNZTGpnZ1p6VUhYUUI4X2M5X1c3NFJlbllXVC1EZ0hXa2ZvdmVLR0p5VnpXN3hCbTR0bE9KWDgwOWpWVXhMaFpWWHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T20:58:42+00:00", "published_display": "08 Jul 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78", "summary": "Kazia Therapeutics director Robert F. Apple was granted 75,000 stock options over ADSs on January 8, 2026, with an exercise price of $6.78 per ADS. These options, awarded for no cash consideration, will vest on January 8, 2027, and have an expiration date of January 8, 2029. This", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-b3f618467f3b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) grants director 100,000 stock options", "summary": "Kazia Therapeutics director Steven R. S. Coffey was granted 100,000 employee stock options over ADSs with an exercise price of $9.10 per ADS. The options were granted for no consideration, vest on January 8, 2027, and expire on January 8, 2029. This transaction was approved by th", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-782de1b8b8d2.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance", "summary": "Kazia Therapeutics reported that Jeffrey Bonacorda, VP, Finance and Controller, received a grant of 150,000 employee stock options (ADSs). These options have an exercise price of $6.78 per ADS, based on the Nasdaq closing price on January 8, 2026, and will vest over three years s", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-070fdddeb4c1.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant", "summary": "KAZIA THERAPEUTICS LTD CEO John E. Friend II was granted 150,000 restricted share units (RSUs) and 500,000 employee stock options. These equity compensation awards, approved by the Remuneration Committee, involve an exercise price of $6.78 per ADS for the options and a vesting sc", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-3f441aa5b6e4.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:09", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Initiates Kazia Therapeutics at Buy With $34 Price Target", "summary": "BTIG has initiated coverage of Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $34. This rating indicates a strong positive outlook for the company's stock by the investment firm.", "url": "https://www.moomoo.com/news/post/72328358/btig-initiates-kazia-therapeutics-at-buy-with-34-price-target", "source_name": "Moomoo", "published_at": "2026-07-02T03:09:21", "published_display": "02 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $34", "summary": "BTIG has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating. The firm has set a price target of $34 for the pharmaceutical company. This new rating suggests a positive outlook from BTIG on Kazia Therapeutics' stock performance.", "url": "https://www.moomoo.com/news/post/72330496/btig-initiates-kazia-therapeutics-kziaus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-01T14:40:36", "published_display": "01 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG initiates Kazia Therapeutics stock with buy on cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWkhodWtMWEpzNnRlNE9Odm1meWt5ZnRLcUtBQlJWM01UTkpDMGV6Q2REeUxHczM3T0Y5UV9BVmp5YjRrWDVPT3p0Mnk2N0kxRUc4R3Q3eWlqbkNHakNjNTlkU0szb1hDeXNNaG81dUN0ZmhYc2JRd0ozYnNZNTgzanoxS3g3MjVuSmlvM0VYUElEdnZ3S2MycnF4Q0RHRE0yU3gwM29rbE93R09JY0V5ZHNjRVV3QkdWaEpBNWozdFY?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T11:08:00+00:00", "published_display": "01 Jul 2026 11:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com", "summary": "BTIG has initiated coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and a price target of $34.00, citing the company's advanced oncology pipeline, particularly its drug paxalisib. While the stock has seen a significant return in the past year, InvestingPro suggests ", "url": "https://ca.investing.com/news/stock-market-news/btig-initiates-kazia-therapeutics-stock-with-buy-on-cancer-drug-93CH-4715757", "source_name": "Investing.com Canada", "published_at": "2026-07-01T11:16:27", "published_display": "01 Jul 2026 11:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA)", "summary": "Kazia Therapeutics Ltd (NASDAQ:KZIA) financial data, including actual results and analyst estimates, is available on TradingView. The platform allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. Us", "url": "https://www.tradingview.com/symbols/NASDAQ-KZIA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:10:28", "published_display": "26 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KZIA SEC Filings - Kazia Therapeuti 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Kazia Therapeutics (KZIA) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It features AI-generated summaries, impact scoring, and sentiment analysis for each filing. Recent fil", "url": "https://www.stocktitan.net/sec-filings/KZIA/page-9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T00:10:28", "published_display": "24 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) grants CFO 200,000 options vesting to 2029", "summary": "Kazia Therapeutics reported that its CFO, James E. Levine, was granted 200,000 employee stock options over ADSs with an exercise price of $13.86 each. The options have a vesting schedule, with one-third vesting on June 1, 2026, and the remainder vesting annually thereafter, expir", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-4-kazia-therapeutics-ltd-insider-trading-activity-745f53de3a7e.html", "source_name": "Stock Titan", "published_at": "2026-06-23T23:11:25", "published_display": "23 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPOEFheHlRV1ExczUyM1V5N3I1bU5fbU9sNXQxZ1NIaWR3em9pYXRNb0VTZlkzSkdBM0dZR09odmNoR0tJLW5ESlVpdlZyb1VzSE4wNlpWUk0xTVZ4eXRhWGdqSjBYYnE1Y3BXT0xoWXlEYUJxTG9UUUlIXy02OUR2WUVNak5oTEQ3cGZETVF4MV9YaFNZTEs4U0VXbklLanV1TnZnWDlnUVh1QVZDS29TOEwyMjRXbTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks", "summary": "This article lists Exchange Traded Funds (ETFs) that invest in Kazia Therapeutics Ltd Sponsored ADR stocks, presenting them as a way to invest in the company with lower risk. It provides a table detailing fund information such as market value, weight, issuer, management style, ex", "url": "https://www.tradingview.com/symbols/NASDAQ-KZIA/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-06-22T04:10:28", "published_display": "22 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Kazia Therapeutics Ltd (KZIA), categorizing its performance by business segments and regional contributions. As of the report updated on March 4, 2025, relevant financial data for FY2021 and FY2022 concerning these breakdowns have not", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T05:10:25", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Kazia Therapeutics Ltd (KZIA), detailing its current stock price, market cap, and various technical indicators. It outlines signals from MACD, RSI, KDJ, and Moving Averages, suggesting a \"Buy\" signal based on current technical analysi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:24", "published_display": "18 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "The article provides a detailed breakdown of Kazia Therapeutics Ltd's (KZIA) shareholder structure, listing major individual and institutional holders. It highlights that Jorey Chernett is the largest individual shareholder with 14.80%, while Alyeska Investment Group, L.P. is a s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T16:40:45", "published_display": "18 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Kazia Therapeutics Ltd (KZIA), indicating a current score of 0.00 with no change from the previous score. It lists key institutional shareholders and their holdings, such as Chernett (Jorey) with a significan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:12", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Kazia Therapeutics Ltd (KZIA), detailing various volatility, financial, and investment risk metrics. It includes data points such as Beta vs S&P 500 index, VaR, maximum drawdown, realized volatility, and Sharpe Ratio across different ti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:12", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Kazia Therapeutics Ltd (KZIA), including future EPS and revenue growth estimates. Based on an analysis of 4 analysts, the consensus target price for KZIA is USD 26.25, suggesting a 90.63% upside. The report highlights a \"Buy\" trend f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:12", "published_display": "18 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Ltd (KZIA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Kazia Therapeutics Ltd (KZIA), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The article also provides the stock's current pri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kzia/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:12", "published_display": "18 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) CFO James E. Levine files initial Form 3", "summary": "Kazia Therapeutics' new Chief Financial Officer, James E. Levine, has filed an initial Form 3 with the SEC, indicating his beneficial ownership status. The filing clarifies his position as a reporting officer but shows no reported purchases, sales, or other transactions of KZIA s", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-3-kazia-therapeutics-ltd-initial-statement-of-beneficial-ownersh-d71ed8601687.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:40:21", "published_display": "15 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum Accelerates - Hot Stock Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPZW9XTjZCaklXSzNBXzJnTHJPbVhUYl8xa2NzV2tnUFhzTkhzV3dfSGYwakk0d1NnajZDYTgyalM4bWMxVTFYaHZGWHZRdld1cVdoRFNKa3E1QjJHUGpSR00xUE91bFYzWnJvUjZ0UUNheEJDSUd5UVhfU3p2RUxoZWVLSmk1MkJybEozS2ZOczktd2tKZVNjZHV2X0VTOFY4MWh6a1h6WFh1RC1jUi1EQnhJc3FTRFk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $32", "summary": "Lake Street has initiated coverage on Kazia Therapeutics (KZIA.US) with a Buy rating. The firm has set a price target of $32 for the company's stock, indicating a bullish outlook.", "url": "https://www.moomoo.com/news/post/71396594/lake-street-initiates-kazia-therapeutics-kziaus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-11T18:09:49", "published_display": "11 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Maintains Target Price $18", "summary": "H.C. Wainwright has reiterated its Buy rating for Kazia Therapeutics (KZIA.US), maintaining a price target of $18. This continued endorsement suggests the firm's confidence in the company's future performance and valuation. The decision to uphold both the rating and the price tar", "url": "https://www.moomoo.com/news/post/71064897/hc-wainwright-maintains-kazia-therapeutics-kziaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-07T01:09:17", "published_display": "07 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Raises Target Price to $30", "summary": "Maxim Group has reiterated its Buy rating on Kazia Therapeutics (KZIA.US) and increased its price target to $30. This update reflects the firm's continued positive outlook on the company's prospects.", "url": "https://www.moomoo.com/news/post/71079791/maxim-group-maintains-kazia-therapeutics-kziaus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-06-05T13:39:23", "published_display": "05 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (KZIA) director details existing ADS option grants", "summary": "Kazia Therapeutics director Ebru Davidson has filed an initial ownership report (Form 3) detailing her existing option grants for the company's American Depositary Shares (ADSs). The filing reveals two ADS option positions, one for 75,000 ADSs with an exercise price of $8.00 and ", "url": "https://www.stocktitan.net/sec-filings/KZIA/form-3-kazia-therapeutics-ltd-initial-statement-of-beneficial-ownersh-4ceedd43c69b.html", "source_name": "Stock Titan", "published_at": "2026-06-04T00:39:59", "published_display": "04 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxNbHNFdG5QNmJuM0FDLTdMUG96cnpGQUIxQ0hEV0wxZnI2ZGc5ZXdjdVg1M1hHakNHRTAwdzhBUEtsaVZNRVEwWXZYV0g0RmtQWmtadVZDMG1MazAyamhTVXpqQWtaaUZQUmZpSzRBdXZCdVZ5MldZUFJyNjF1QVMwYzl5N2MzX0g0WDhaV25IVjJwSkVJa3lrY1V6YmVnSlpvZkpkVUswRGRuMEt5ZHF3SjJEQmhycEhneURIa25VaVgwU3hIOE1lV0NrQTcwOFhncC1kX2xTcG5CZzlYM3lVWTdhcndLWnhCNDNpNzVMeV9BQ0FyV3RoejVkcjVSYTRoR2tMV2ZsNkFhb3RQaWZuRjJ3?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kazia Therapeutics Appoints James Levine as Chief Financial Officer", "summary": "Kazia Therapeutics has announced the appointment of James Levine as its new Chief Financial Officer, effective immediately. Mr. Levine brings extensive experience in biotech finance and will be crucial in managing the company's financial operations and strategic growth as it adva", "url": "https://www.moomoo.com/news/post/70928726/press-release-kazia-therapeutics-appoints-james-levine-as-chief-financial", "source_name": "Moomoo", "published_at": "2026-06-03T02:39:59", "published_display": "03 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Appoints James Levine as Chief Financial Officer", "summary": "Kazia Therapeutics has appointed James Levine as its Chief Financial Officer, effective June 1, 2026. Mr. Levine brings over two decades of experience in investment banking and financial leadership at publicly traded biotech companies, including roles at Cardiff Oncology and Cida", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kazia-therapeutics-appoints-james-levine-113000494.html", "source_name": "Market source", "published_at": "2026-06-02T23:11:25", "published_display": "02 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO", "summary": "Kazia Therapeutics has filed a prospectus supplement to register 10,700,211 American Depositary Shares (ADSs), representing 5,350,105,500 ordinary shares. Concurrently, the company announced the appointment of James Levine as its Chief Financial Officer, effective June 1, 2026, w", "url": "https://www.stocktitan.net/sec-filings/KZIA/424b3-kazia-therapeutics-ltd-prospectus-filed-pursuant-to-rule-424-b--84a4c2a60f27.html", "source_name": "Stock Titan", "published_at": "2026-06-02T15:08:57", "published_display": "02 Jun 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026", "summary": "Kazia Therapeutics Limited has announced the appointment of James Levine as its Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and financial leadership at publicly traded biotech companies, including roles at Ca", "url": "https://www.marketscreener.com/news/kazia-therapeutics-limited-announces-appointment-of-james-levine-to-chief-financial-officer-effecti-ce7f5ddedb81ff2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-02T14:39:13", "published_display": "02 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO", "summary": "Kazia Therapeutics Limited announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Mr. Levine's compensation package includes an annual base salary of US$475,000, a target bonus of 40% of base salary, and options for 200,000 American ", "url": "https://www.stocktitan.net/sec-filings/KZIA/6-k-kazia-therapeutics-ltd-current-report-foreign-issuer-fecd25e028c4.html", "source_name": "Stock Titan", "published_at": "2026-06-02T13:09:03", "published_display": "02 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kazia-therapeutics-expands-ongoing-phase-113000332.html", "source_name": "PR Newswire", "published_at": "2026-05-26T11:30:00+00:00", "published_display": "26 May 2026 11:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst (NASDAQ:KZIA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPVTNPSTIyLVI4TFQtZXRtejBUZ1BURzV0SjdwelF6anhvMXNpRjNvZ3A0UlJQLWtkZkxaUTNDQWRxWDNvekYxWmdfeEYwY0JNTGtyX25qRG01NGJqR2Q2aUlnSjZyQ01rbWRIMU9zRkVtT0laN2c4TkhJUk5HZWwyUVFlSWlMLWIwdmpQNnBWX1pCSFAtOHVfRnNDTWV3bDhNNEs0eE1yOE1sUlpOVDI1YU9B?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQTEZRc0RVRmFveTZXMG1SYS1TNkZtaDMzMWFtQjc4aTJHamNBVlRaX3BFazEzMnFCWXp0bEZVV0ozNGhfWndqWVRzTkVVME5lVnpNNHl1akFOZzZYUlQwRFREQVFDM2dPMzAyS1ZqN1cwU1NKZnI2cVJfR2NZNlZQTUotbFl6X0ZiWi1pZDRLTnBTbldVQndmMklxSjl5dkdvSmZNOGE4R0R1QlVJdDZz?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kazia adds AI-built cancer drug platform with lead candidate MSETC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTm9HM0Z5ZElxTnRhbkNFZVhjSmRsU0R4ZTdwT0hjQWxhV3VNSXlTSDc1ODc1dVVHQjhON1BBZ2pJUS1KdjRyRHh2cFdueDB4MUhGajNRZ2ZaS1BmbEh4Zi1yWnh3OHZ3T1V0UXAzWlhwTFNQRHVfVmtHWHpoWjBzenRoUUdzeWZ1S2ZHcjFvRVRsb01rd0g1alg1cWhHeDcxdHozbkcxNktsMDg0WUM5bVNxaTBncXFTNjVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 46, "sentiment_summary": {"positive": 17, "negative": 2, "neutral": 27, "score": 58, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 13.56, "latest_week": "2026-07-10", "one_week_move": 2.3, "four_week_move": -5.0, "twelve_week_move": 22.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.452135, "market_dynamics_buy_signal": false, "relative_strength": 28.407587, "fair_value_gap": -15.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 40.6948, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.3% over one week, -5.0% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Moomoo", "count": 6}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Investing.com", "count": 1}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 7}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.3% over one week, -5.0% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director"}], "updated_at": "2026-07-16T08:14:18.644078+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}